CAPR 9.74 (+2.74%)
US14070B3096BiotechnologyBiotechnology

Capricor Therapeutics (CAPR) Stock Highlights

9.74 | +2.74%
2025-04-03 05:44:25
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The companys development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Statistics

Range Today
9.21 9.93
Volume Today 1.23M
Range 1 Year
3.52 23.4
Volume 1 Year 356.57M
Range 3 Year
2.68 23.4
Volume 3 Year 439.76M
Range 10 Year
0.88 86.5
Volume 10 Year 1.34B

Highlights

Market Capitalization 525.28M (small)
Floating Shares 40.13M
Current Price 9.74
Price To Earnings -10.25
Price To Revenue 16.85
Price To Book 3.6
Earnings Per Share -1.15
Payout Ratio 0%

Performance

Latest +2.74%
1 Month -36.21%
3 Months -30.53%
6 Months -33.1%
1 Year +39.74%
3 Years +169.81%
5 Years +818.87%
10 Years -88.05%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.